Key Highlights

  • Collaboration Revenue was USD 4.2 million, against USD 9.6 million a year earlier.
  • Research and development expenses were USD 82.3 million, up from USD 62.2 million.
  • General and administrative expenses rose to USD 13.5 million from USD 10.3 million.
  • The IPO closed on March 2, 2026, with net proceeds of about USD 369.3 million.

Generate Biomedicines (NASDAQ:GENB) reported third-quarter 2026 collaboration revenue of USD 4.2 million, against an estimate of USD 7.75 million. Loss per share was USD 0.68, against an estimate of USD 0.56. The company develops product candidates through The Generate Platform, and its filing names GB-0895, GB-4362 and GB-5267 among its product candidates.

Revenue, Operating Expenses and Loss

Collaboration revenue was USD 4,220 thousand for the quarter, against USD 9,634 thousand a year earlier. For the nine months, it was USD 17,758 thousand, against USD 28,582 thousand.

Research and development expenses were USD 82,254 thousand for the quarter, against USD 62,151 thousand. General and administrative expenses were USD 13.5 million, against USD 10.3 million. The USD 3.2 million increase was driven mainly by a USD 1.8 million rise in stock-based compensation expense linked to stock Options granted to employees. Total operating expenses were USD 95.7 million, against USD 72.4 million, and loss from operations was USD 91.5 million, against USD 62.8 million.

For the nine months, Research and Development expenses were USD 204.4 million, against USD 168.7 million. General and administrative expenses were USD 40.6 million, against USD 31.0 million. Total operating expenses were USD 245.0 million, and loss from operations was USD 227.2 million, against USD 171.1 million. Net loss for the nine months was USD 216.6 million.

IPO and Going Concern Disclosure

On March 2, 2026, the company closed its IPO, issuing and selling 25,000,000 shares of common stock at USD 16.00 per share. Net proceeds were approximately USD 369.3 million, after USD 30.7 million of Underwriting discounts, commissions and offering expenses.

The accumulated Deficit was USD 892.7 million at September 30, 2026. The filing states that, as of December 31, 2025, the company had concluded there was substantial doubt about its ability to continue as a going concern. It states that, upon closing of the IPO and receipt of the proceeds, that doubt was alleviated.

Balance Sheet and Equity Plans

Accrued expenses and other current liabilities totaled USD 43.6 million at September 30, 2026, against USD 42.2 million at December 31, 2025. Accrued research and development was USD 28.3 million, against USD 23.4 million, and compensation and benefit accruals were USD 11.0 million, against USD 13.8 million.

Concurrent with the IPO in February 2026, all unissued shares reserved for grant under the 2019 Plan ceased to be available, with future issuances intended to be made under the 2026 Equity Incentive Plan. A prior agreement with a related party was terminated on February 26, 2026, and the filing records related party amounts of USD 0.1 million for the quarter and USD 0.3 million for the nine months.

The filing also records the valuation inputs for a warrant: a term of 0.1 years, Volatility of 73.0% and a risk-free Interest Rate of 3.7%, with the Fair Value of Series A convertible preferred stock per share at USD 11.44, against USD 9.29 at the prior year end.

The reported items for the quarter are collaboration revenue of USD 4.2 million, research and development expenses of USD 82.3 million, the nine-month net loss of USD 216.6 million and the IPO proceeds. The company is listed on the Nasdaq Global Select Market.